Vol. 3 No. 6 (2023)
Reimbursement Recommendations

Vericiguat (Verquvo)

Published June 29, 2023

Key Messages

  • CADTH recommends that Verquvo be reimbursed by public drug plans for the treatment of chronic heart failure (HF) as an adjunct to standard of care therapy if certain conditions are met.
  • Verquvo should only be covered to treat adult patients: whose heart is unable to pump enough blood to keep up with the body’s needs because the heart is too weak (i.e., HF with reduced ejection fraction); who are considered to be symptomatic (e.g., slight limitation in physical activity, defined as New York Heart Association [NYHA] functional classification class II; a marked limitation in physical activity, defined as NYHA class III; or symptoms even at rest, defined as NYHA class IV); and who had a recent hospitalization or needed to receive IV medicines.
  • Verquvo should only be reimbursed if the price of Verquvo is reduced.